Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 57

1.

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.

Smith KM, Eyal E, Weintraub D; ADAGIO Investigators.

JAMA Neurol. 2015 Jan;72(1):88-95. doi: 10.1001/jamaneurol.2014.2472.

PMID:
25420207
2.

Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).

Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J; STACCATO study investigators.

Pharmacotherapy. 2014 Dec;34(12):1250-8. doi: 10.1002/phar.1500. Epub 2014 Oct 14.

PMID:
25314256
3.

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.

Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R; International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI); 23andMe; GenePD; NeuroGenetics Research Consortium (NGRC); Hussman Institute of Human Genomics (HIHG); Ashkenazi Jewish Dataset Investigator; Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC); Greek Parkinson's Disease Consortium; Alzheimer Genetic Analysis Group, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB.

Nat Genet. 2014 Sep;46(9):989-93. doi: 10.1038/ng.3043. Epub 2014 Jul 27.

4.

Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial.

Jennings D, Eberly S, Oakes D, Seibyl J, Marek K, Shoulson I; Parkinson Study Group PRECEPT Investigators.

J Parkinsons Dis. 2014;4(4):629-38. doi: 10.3233/JPD-140383.

PMID:
25062961
5.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
6.

A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.

Nicholas AP, Borgohain R, ChanĂ¡ P, Surmann E, Thompson EL, Bauer L, Whitesides J, Elmer LW; SP921 Study Investigators.

J Parkinsons Dis. 2014;4(3):361-73. doi: 10.3233/JPD-130320.

PMID:
24643203
7.

Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.

Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, Hsu A, O'Connell M, Kell S, Gupta S; APEX-PD Investigators.

Parkinsonism Relat Disord. 2014 Feb;20(2):142-8. doi: 10.1016/j.parkreldis.2013.08.017. Epub 2013 Sep 5.

8.

Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.

Elmer LW.

Parkinsonism Relat Disord. 2013 Nov;19(11):930-6. doi: 10.1016/j.parkreldis.2013.06.001. Epub 2013 Jul 10.

PMID:
23849501
9.

Facile carbon monoxide reduction at intramolecular frustrated phosphane/borane Lewis pair templates.

Sajid M, Elmer LM, Rosorius C, Daniliuc CG, Grimme S, Kehr G, Erker G.

Angew Chem Int Ed Engl. 2013 Feb 18;52(8):2243-6. doi: 10.1002/anie.201208750. Epub 2013 Jan 15. No abstract available.

PMID:
23322704
10.

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.

LeWitt PA, Boroojerdi B, Surmann E, Poewe W; SP716 Study Group; SP715 Study Group.

J Neural Transm. 2013 Jul;120(7):1069-81. doi: 10.1007/s00702-012-0925-5. Epub 2012 Dec 4.

11.

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W; SAD-PD Study Group.

Neurology. 2012 Apr 17;78(16):1229-36. doi: 10.1212/WNL.0b013e3182516244. Epub 2012 Apr 11.

12.

Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2.

Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T; PD GWAS Consortium.

Ann Neurol. 2012 Mar;71(3):370-84. doi: 10.1002/ana.22687.

13.

Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study.

Elmer LW, Surmann E, Boroojerdi B, Jankovic J.

Parkinsonism Relat Disord. 2012 Jun;18(5):488-93. doi: 10.1016/j.parkreldis.2012.01.008. Epub 2012 Feb 10.

PMID:
22326237
14.

Copy number variation in familial Parkinson disease.

Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, Halter C, Doheny KF, Gusella JF, Nichols WC, Myers RH, Foroud T, DeStefano AL; PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories.

PLoS One. 2011;6(8):e20988. doi: 10.1371/journal.pone.0020988. Epub 2011 Aug 2.

15.

Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience.

Kanjwal K, Karabin B, Sheikh M, Elmer L, Kanjwal Y, Saeed B, Grubb BP.

Pacing Clin Electrophysiol. 2011 Jun;34(6):750-5. doi: 10.1111/j.1540-8159.2011.03047.x. Epub 2011 Mar 16.

PMID:
21410722
16.

Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.

Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE; Parkinson Study Group DATATOP and PRECEPT investigators.

Mov Disord. 2011 Mar;26(4):608-13. doi: 10.1002/mds.23581. Epub 2011 Feb 1.

PMID:
21287602
17.

Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.

Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators, Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, Goetz C.

Mov Disord. 2010 Sep 15;25(12):1801-8. doi: 10.1002/mds.23006.

PMID:
20669311
18.

Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease.

Simon DK, Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Nichols WC, Foroud T; Parkinson Study Group-PROGENI Investigators.

BMC Med Genet. 2010 Apr 1;11:53. doi: 10.1186/1471-2350-11-53.

19.

A long-term study of istradefylline in subjects with fluctuating Parkinson's disease.

Factor S, Mark MH, Watts R, Struck L, Mori A, Ballerini R, Sussman NM; Istradefylline 6002-US-007 Study Group.

Parkinsonism Relat Disord. 2010 Jul;16(6):423-6. doi: 10.1016/j.parkreldis.2010.02.014. Epub 2010 Mar 24. No abstract available.

PMID:
20338800
20.

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group DATATOP and PRECEPT investigators.

Mov Disord. 2009 Dec 15;24(16):2370-8. doi: 10.1002/mds.22828.

PMID:
19908310
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk